ZA200202822B - Oncolytic combinations for the treatment of cancer. - Google Patents

Oncolytic combinations for the treatment of cancer.

Info

Publication number
ZA200202822B
ZA200202822B ZA200202822A ZA200202822A ZA200202822B ZA 200202822 B ZA200202822 B ZA 200202822B ZA 200202822 A ZA200202822 A ZA 200202822A ZA 200202822 A ZA200202822 A ZA 200202822A ZA 200202822 B ZA200202822 B ZA 200202822B
Authority
ZA
South Africa
Prior art keywords
cancer
treatment
oncolytic
combinations
oncolytic combinations
Prior art date
Application number
ZA200202822A
Other languages
English (en)
Inventor
Jerome Herbert Fleisch
Jason Scott Sawyer
Douglas Wade Beight
William Thomas Mcmillen
Roger Stuart Benjamin
Beverly Ann Teicher
Edward C R Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA200202822B publication Critical patent/ZA200202822B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
ZA200202822A 1999-11-11 2002-04-10 Oncolytic combinations for the treatment of cancer. ZA200202822B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16478699P 1999-11-11 1999-11-11

Publications (1)

Publication Number Publication Date
ZA200202822B true ZA200202822B (en) 2003-09-23

Family

ID=22596085

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200202822A ZA200202822B (en) 1999-11-11 2002-04-10 Oncolytic combinations for the treatment of cancer.

Country Status (22)

Country Link
EP (1) EP1231938A2 (es)
JP (1) JP2003513916A (es)
KR (1) KR20020069512A (es)
CN (1) CN1390139A (es)
AR (1) AR032432A1 (es)
AU (1) AU778829B2 (es)
BR (1) BR0015490A (es)
CA (1) CA2391416A1 (es)
CZ (1) CZ20021551A3 (es)
EA (1) EA200200545A1 (es)
HK (1) HK1050132A1 (es)
HU (1) HUP0204449A3 (es)
IL (1) IL148579A0 (es)
MX (1) MXPA02004733A (es)
NO (1) NO20022245L (es)
NZ (1) NZ517667A (es)
PE (1) PE20010701A1 (es)
PL (1) PL355172A1 (es)
SK (1) SK6492002A3 (es)
TR (1) TR200201245T2 (es)
WO (1) WO2001034137A2 (es)
ZA (1) ZA200202822B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034198A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
CA2408622A1 (en) * 2000-05-09 2001-11-15 Creighton University Methods for inhibiting proliferation and inducing apoptosis in cancer cells
JP2004505047A (ja) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
CN1302782C (zh) * 2005-01-17 2007-03-07 北京京卫燕康药物研究所有限公司 盐酸吉西他滨溶液型注射剂
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
EP1979311B1 (en) 2005-12-22 2012-06-13 High Point Pharmaceuticals, LLC Phenoxy acetic acids as ppar delta activators
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
AU2007307597A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Carboxylic acid derivatives
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
EP2914587A1 (de) 2012-10-31 2015-09-09 Bayer CropScience AG Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
CN103319466B (zh) * 2013-07-04 2016-03-16 郑州大学 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
CN1390139A (zh) 2003-01-08
PL355172A1 (en) 2004-04-05
BR0015490A (pt) 2002-07-09
CZ20021551A3 (cs) 2003-02-12
NO20022245L (no) 2002-07-09
NO20022245D0 (no) 2002-05-10
SK6492002A3 (en) 2003-09-11
HUP0204449A2 (hu) 2003-04-28
PE20010701A1 (es) 2001-07-07
TR200201245T2 (tr) 2004-08-23
AU1599001A (en) 2001-06-06
KR20020069512A (ko) 2002-09-04
AR032432A1 (es) 2003-11-12
WO2001034137A2 (en) 2001-05-17
EP1231938A2 (en) 2002-08-21
WO2001034137A3 (en) 2002-02-14
HUP0204449A3 (en) 2006-02-28
IL148579A0 (en) 2002-09-12
CA2391416A1 (en) 2001-05-17
MXPA02004733A (es) 2002-08-30
JP2003513916A (ja) 2003-04-15
AU778829B2 (en) 2004-12-23
HK1050132A1 (zh) 2003-06-13
NZ517667A (en) 2004-05-28
EA200200545A1 (ru) 2002-12-26

Similar Documents

Publication Publication Date Title
ZA200202461B (en) Compounds for the treatment of ischemia.
ZA200202822B (en) Oncolytic combinations for the treatment of cancer.
AU2020501A (en) Chemotherapy treatment
AU6048201A (en) Quinazoline derivatives for the treatment of tumours
ZA200003236B (en) Combination therapy for the treatment of migraine.
ZA200105690B (en) Novel treatment.
AU1916601A (en) Oncolytic combinations for the treatment of cancer
AU4498201A (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment ofpain
ZA200107736B (en) Improved cancer treatment with temozolomide.
AU1916501A (en) Oncolytic combinations for the treatment of cancer
HUP0101947A3 (en) Combination for the treatment of tumors
ZA200205470B (en) Virus strains for the oncolytic treatment of cancer.
AU1917101A (en) Oncolytic combinations for the treatment of cancer
AU1595001A (en) Oncolytic combinations for the treatment of cancer
ZA200204156B (en) Water treatment.
AU1595101A (en) Oncolytic combinations for the treatment of cancer
ZA200203166B (en) Treatment of cancer.
HK1050533A1 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer.
AU2001257325A1 (en) Cancer treatment
GB0026015D0 (en) Cancer treatment
ZA200003235B (en) Combination therapy for the treatment of migraine.
ZA200002338B (en) Combination therapy for the treatment of migraine.
ZA200109120B (en) Use of Arylalkanoylpyridazines.
AU1592901A (en) Oncolytic combinations for the treatment of cancer
ZA200002343B (en) Combination therapy for the treatment of migraine.